Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1/2 2Phase 1 2Phase NA 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia 2Recurrence 1Burkitt Lymphoma 1

Interventions

Rituximab 47Cyclophosphamide 45fludarabine 22Filgrastim 21Lenalidomide 18fludarabine phosphate 17Prednisone 16Radiotherapy 15Peripheral Blood Stem Cell Transplantation 15Etoposide 15Vincristine 14Doxorubicin 14Melphalan 13Busulfan 13pembrolizumab 11Tacrolimus 11Methotrexate 10Gemcitabine 10ibrutinib 9Bendamustine Hydrochloride 9Alemtuzumab 9obinutuzumab 8Bortezomib 8Vorinostat 7Mycophenolic Acid 7Granulocyte Colony-Stimulating Factor 7Carboplatin 7Azacitidine 7venetoclax 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma × nelarabine × Clear all
NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00981799 2020-10-01

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Terminated
23 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡